Article

Current treatment of parotid hemangiomas

The Laryngoscope (Impact Factor: 1.98). 07/2011; 121(8):1642 - 1650. DOI:10.1002/lary.21358
Source: PubMed

ABSTRACT Objectives/Hypothesis:Parotid hemangiomas are the most common salivary gland tumors in children. Their treatment has posed a challenge because of the lesions' expansive growth, resistance to treatment, and relationship with the facial nerve. Various treatment modalities have been attempted, and promising results have been achieved with surgical resection alone or in conjunction with endovascular sclerotherapy. Recently, bleomycin and oral propranolol have been introduced, and the results thus far are promising. Here we elucidate the treatment options and propose a treatment algorithm for parotid hemangiomas.Study Design:Retrospective chart review.Methods:We conducted a retrospective chart review of patients from 2004 to 2009 with hemangiomas involving the parotid gland. We included 56 patients and relevant parameters.Results:Seventy percent of patients were female. The female-to-male ratio was 2.3 to 1. Thirty-nine percent had unilateral parotid hemangiomas, 12.5% had cutaneous segmental hemangiomas. All 22 patients who underwent systemic steroid therapy responded initially, but 68% of these rebounded after cessation of therapy. Sixteen patients (29%) underwent surgery with excellent results (facial symmetry, restoration of contour, preserved facial nerve function). Seven (44%) patients received sclerotherapy 24 to 48 hours before surgery, and five (8%) received endovascular sclerotherapy alone. Ten patients were treated medically with oral propranolol. Eight of 10 had significant shrinkage of the lesion within the first month of treatment. There were no reported side effects.Conclusions:Multiple treatment regimens have been used to successfully treat parotid hemangiomas. Although propranolol is a recent addition, it seems most promising. Further evaluation is warranted.

0 1
 · 
0 Bookmarks
 · 
228 Views
  • [show abstract] [hide abstract]
    ABSTRACT: Abstract Conclusions: Parotidectomy remains the mainstay of treatment for both benign and malignant lesions of the pediatric parotid gland. Adjuvant radiation therapy should be used judiciously in pediatric patients due to the higher risk of post-irradiation complications. Objective: The purpose of this study was to define the incidence and treatment of pediatric parotid tumors, and to determine what factors are useful in the management of these lesions. Methods: From June 2002 to June 2012, 22 patients ≤18 years of age with parotid mass were treated at Chonnam National University Hospital. Information on patient characteristics, clinical and histopathologic tumor characteristics, and treatment modalities and their results was obtained from the medical records. Results: The 22 patients comprised 11 males and 11 females. Eighteen patients had a benign tumor and four patients had a malignant tumor. The most common benign tumor was pleomorphic adenoma (63.6%) and the most common malignant tumor was mucoepidermoid carcinoma (9%). The most common treatment was superficial parotidectomy. Three patients required adjuvant radiotherapy. None of the patients had major complications or facial nerve palsy.
    Acta oto-laryngologica 08/2013; · 0.98 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.
    PEDIATRICS 12/2012; · 4.47 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.
    Pediatric Dermatology 03/2013; 30(2):182-91. · 1.04 Impact Factor

Full-text (2 Sources)

View
353 Downloads
Available from
Oct 4, 2012